litlas
Log inCreate account

Edward A. Stadtmauer

Active 1992–2025

140
Papers
31,055
Citations
88
h-index
131
i10-index

Citations

Citations per year for Edward A. Stadtmauer1989: 1 citations1991: 1 citations1992: 1 citations1993: 3 citations1994: 7 citations1995: 8 citations1996: 12 citations1997: 19 citations1998: 10 citations1999: 24 citations2000: 29 citations2001: 26 citations2002: 50 citations2003: 78 citations2004: 66 citations2005: 78 citations2006: 125 citations2007: 156 citations2008: 184 citations2009: 210 citations2010: 247 citations2011: 264 citations2012: 174 citations2013: 277 citations2014: 258 citations2015: 277 citations2016: 266 citations2017: 248 citations2018: 245 citations2019: 789 citations2020: 1,021 citations2021: 1,063 citations2022: 847 citations2023: 576 citations2024: 1,061 citations2025: 547 citations2026: 18 citations1990: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,810 citing papers, 31.3% of this breakdownChina: 870 citing papers, 7.1% of this breakdownGermany: 834 citing papers, 6.8% of this breakdownUnited Kingdom: 676 citing papers, 5.6% of this breakdownItaly: 595 citing papers, 4.9% of this breakdownFrance: 497 citing papers, 4.1% of this breakdownSpain: 455 citing papers, 3.7% of this breakdownCanada: 385 citing papers, 3.2% of this breakdownNetherlands: 369 citing papers, 3% of this breakdownAustralia: 309 citing papers, 2.5% of this breakdownSwitzerland: 262 citing papers, 2.2% of this breakdownJapan: 220 citing papers, 1.8% of this breakdown
0%31.3%Other 23.8%

Institutions

Fields

  • Medicine76.3%
  • Biochemistry, Genetics and Molecular Biology15.1%
  • Immunology and Microbiology5.8%
  • Economics, Econometrics and Finance1%
  • Engineering0.3%
  • Neuroscience0.2%
  • Other1.3%

Topics

  • CAR-T cell therapy research10.8%
  • Multiple Myeloma Research and Treatments8.1%
  • Protein Degradation and Inhibitors4.3%
  • Immunotherapy and Immune Responses3.8%
  • Immune Cell Function and Interaction3.3%
  • Virus-based gene therapy research3%
  • Other66.7%

Coauthors

All papers

Open in search
  1. CRISPR-engineered T cells in patients with refractory cancer

    Authors: Edward A. Stadtmauer, Joseph A. Fraietta, Megan M. Davis, Adam D. Cohen, Kristy Weber, Eric Lancaster, Patricia Mangan, Irina Kulikovskaya, Minnal Gupta, Fang Chen, Lifeng Tian, Vanessa Gonzalez, Jun Xu, In-Young Jung, J. Joseph Melenhorst, Gabriela Plesa, Joanne Shea, Tina Matlawski, Amanda Cervini, Avery L. Gaymon, Stephanie Desjardins, Anne Lamontagne, January Salas-McKee, Andrew D. Fesnak, Donald L. Siegel, Bruce L. Levine, Julie K. Jadlowsky, Regina M. Young, Anne Chew, Wei‐Ting Hwang, Elizabeth O. Hexner, Beatriz M. Carreno, Christopher L. Nobles, Frederic D. Bushman, Kevin R. Parker, Yanyan Qi, Ansuman T. Satpathy, Howard Y. Chang, Yangbing Zhao, Simon F. Lacey, Carl H. June - Science 2020 cited by 1,484

  2. T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy

    Authors: Guido Ghilardi, Joseph A. Fraietta, James N. Gerson, Vivianna M. Van Deerlin, Jennifer J.D. Morrissette, Gabriel C. Caponetti, Luca Paruzzo, Jaryse Harris, Elise A. Chong, Sandra P. Susanibar-Adaniya, Jakub Svoboda, Sunita D. Nasta, Ositadimma Ugwuanyi, Daniel J. Landsburg, Eugenio Fardella, Adam Waxman, Emeline R. Chong, Vrutti Patel, Raymone Pajarillo, Irina Kulikovskaya, David Lieberman, Adam D. Cohen, Bruce L. Levine, Edward A. Stadtmauer, Noelle V. Frey, Dan T. Vogl, Elizabeth O. Hexner, Stefan K. Barta, David L. Porter, Alfred L. Garfall, Stephen J. Schuster, Carl H. June, Marco Ruella - Nature Medicine 2024 cited by 256

  3. B cell maturation antigen–specific CAR T cells are clinically active in multiple myeloma

    Authors: Adam D. Cohen, Alfred L. Garfall, Edward A. Stadtmauer, J. Joseph Melenhorst, Simon F. Lacey, Eric Lancaster, Dan T. Vogl, Brendan M. Weiss, Karen Dengel, Annemarie Nelson, Gabriela Plesa, Fang Chen, Megan M. Davis, Wei‐Ting Hwang, Regina M. Young, Jennifer L. Brogdon, Randi Isaacs, Iulian Pruteanu-Malinici, Don L. Siegel, Bruce L. Levine, Carl H. June, Michael C. Milone - Journal of Clinical Investigation 2019 cited by 790

  4. Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma

    Authors: Gerald P. Linette, Edward A. Stadtmauer, Marcela V. Maus, Aaron P. Rapoport, Bruce L. Levine, Lyndsey Emery, Leslie A. Litzky, Adam Bagg, Beatriz M. Carreno, Patrick J. Cimino, Gwendolyn Binder-Scholl, Dominic Smethurst, Andrew B. Gerry, Nick Pumphrey, Alan Bennett, Joanna E. Brewer, Joseph Dukes, Jane Harper, Helen K. Tayton-Martin, Bent K. Jakobsen, Namir J. Hassan, Michael Kalos, Carl H. June - Blood 2013 cited by 1,163

  5. Mitigation of chromosome loss in clinical CRISPR-Cas9-engineered T cells

    Authors: Connor A. Tsuchida, Nadav Brandes, Raymund Bueno, Marena Trinidad, Thomas Mazumder, Bingfei Yu, Byungjin Hwang, Christopher Chang, Jamin Liu, Yang Sun, Caitlin R. Hopkins, Kevin R. Parker, Yanyan Qi, Laura Hofman, Ansuman T. Satpathy, Edward A. Stadtmauer, J.H.D. Cate, Justin Eyquem, Joseph A. Fraietta, Carl H. June, Howard Y. Chang, Chun Ye, Jennifer A. Doudna - Cell 2023 cited by 196

  6. NY-ESO-1–specific TCR–engineered T cells mediate sustained antigen-specific antitumor effects in myeloma

    Authors: Aaron P. Rapoport, Edward A. Stadtmauer, Gwendolyn Binder-Scholl, Olga Goloubeva, Dan T. Vogl, Simon F. Lacey, Ashraf Badros, Alfred L. Garfall, Brendan M. Weiss, Jeffrey Finklestein, Irina Kulikovskaya, Sanjoy K. Sinha, Shari S. Kronsberg, Minnal Gupta, Sarah Bond, Luca Melchiori, Joanna E. Brewer, Alan Bennett, Andrew B. Gerry, Nicholas J. Pumphrey, Daniel Williams, Helen K Tayton- Martin, Lilliam Ribeiro, Tom Holdich, Saul Yanovich, Nancy M. Hardy, Jean A. Yared, Naseem Kerr, Sunita Philip, Sandra Westphal, Don L. Siegel, Bruce L. Levine, Bent K. Jakobsen, Michael Kalos, Carl H. June - Nature Medicine 2015 cited by 848

  7. Identification of a Titin-Derived HLA-A1–Presented Peptide as a Cross-Reactive Target for Engineered MAGE A3–Directed T Cells

    Authors: Brian Cameron, Andrew B. Gerry, Joseph Dukes, Jane Harper, Vivekanandan Kannan, Frayne Bianchi, Francis Grand, Joanna E. Brewer, Minnal Gupta, Gabriela Plesa, Giovanna Bossi, Annelise Vuidepot, Alex S. Powlesland, Alison Legg, Katherine J. Adams, Alan Bennett, Nicholas J. Pumphrey, Daniel Williams, Gwendolyn Binder-Scholl, Irina Kulikovskaya, Bruce L. Levine, James L. Riley, Angel Varela‐Rohena, Edward A. Stadtmauer, Aaron P. Rapoport, Gerald P. Linette, Carl H. June, Namir J. Hassan, Michael Kalos, Bent K. Jakobsen - Science Translational Medicine 2013 cited by 677

  8. Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group

    Authors: Noopur Raje, Elias Anaissie, Shaji Kumar, Sagar Lonial, Thomas G Martin, Morie A. Gertz, Amrita Krishnan, Parameswaran Hari, Heinz Ludwig, Elizabeth O’Donnell, Andrew J. Yee, Jonathan L. Kaufman, Adam D. Cohen, Laurent Garderet, Ashutosh F Wechalekar, Evangelos Terpos, Navin Khatry, Rubén Niesvizky, Qing Yi, Douglas Joshua, Tapan Saikia, Nelson Leung, Monika Engelhardt, Mohamad Mothy, Andrew R. Branagan, Ajai Chari, Tony Reiman, Brea Lipe, Joshua Richter, S. Vincent Rajkumar, Jesús F. San Miguel, Kenneth C. Anderson, Edward A. Stadtmauer, Rao Prabhala, Phillip McCarthy, Nikhil C. Munshi - The Lancet Haematology 2022 cited by 191

  9. T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed multiple myeloma

    Authors: Alfred L. Garfall, Ehren K. Dancy, Adam D. Cohen, Wei‐Ting Hwang, Joseph A. Fraietta, Megan M. Davis, Bruce L. Levine, Don L. Siegel, Edward A. Stadtmauer, Dan T. Vogl, Adam Waxman, Aaron P. Rapoport, Michael C. Milone, Carl H. June, J. Joseph Melenhorst - Blood Advances 2019 cited by 229

  10. Effect of Recombinant Zoster Vaccine on Incidence of Herpes Zoster After Autologous Stem Cell Transplantation

    Authors: Adriana Bastidas, Javier de la Serna, Mohamed El Idrissi, Lidia Oostvogels, Philippe Quittet, Javier López‐Jiménez, Filiz Vural, David Pohlreich, Tsila Zuckerman, Nicolas C. Issa, Gianluca Gaïdano, Je‐Jung Lee, Sunil Abhyankar, Carlos Solano, Jaime Pérez de Oteyza, Michael J. Satlin, Stefan Schwartz, Magda Campins, Alberto Rocci, Carlos Vallejo Llamas, Dong‐Gun Lee, Sen Mui Tan, Anna Johnston, Andrew Grigg, Michael J. Boeckh, Laura Cámpora, Marta López‐Fauqued, Thomas C. Heineman, Edward A. Stadtmauer, Keith M. Sullivan, for the ZOE-HSCT Study Group Collaborators - JAMA 2019 cited by 257

  11. Changes in Bone Marrow Tumor and Immune Cells Correlate with Durability of Remissions Following BCMA CAR T Therapy in Myeloma

    Authors: Kavita M. Dhodapkar, Adam D. Cohen, Akhilesh Kaushal, Alfred L. Garfall, Renee Julia Manalo, Allison R. Carr, Samuel S. McCachren, Edward A. Stadtmauer, Simon F. Lacey, J. Joseph Melenhorst, Carl H. June, Michael C. Milone, Madhav V. Dhodapkar - Blood Cancer Discovery 2022 cited by 108

  12. Long-Term Outcomes From a Randomized Dose Optimization Study of Chimeric Antigen Receptor Modified T Cells in Relapsed Chronic Lymphocytic Leukemia

    Authors: Noelle V. Frey, Saar Gill, Elizabeth O. Hexner, Stephen J. Schuster, Sunita D. Nasta, Alison W. Loren, Jakub Svoboda, Edward A. Stadtmauer, Daniel J. Landsburg, Anthony R. Mato, Bruce L. Levine, Simon F. Lacey, J. Joseph Melenhorst, Elizabeth Veloso, Avery L. Gaymon, Edward Pequignot, Xinhe Shan, Wei‐Ting Hwang, Carl H. June, David L. Porter - Journal of Clinical Oncology 2020 cited by 185

  13. Combined autophagy and proteasome inhibition

    Authors: Dan T. Vogl, Edward A. Stadtmauer, Kay-See Tan, Daniel F. Heitjan, Lisa E. Davis, Laura Pontiggia, Reshma Rangwala, Shengfu Piao, Yunyoung C Chang, Emma C. Scott, Thomas Paul, Charles W. Nichols, David Porter, Janeen Kaplan, G. Mallon, James E. Bradner, Ravi K. Amaravadi - Autophagy 2014 cited by 373

  14. Anti-BCMA/CD19 CAR T Cells with Early Immunomodulatory Maintenance for Multiple Myeloma Responding to Initial or Later-Line Therapy

    Authors: Alfred L. Garfall, Adam D. Cohen, Sandra P. Susanibar-Adaniya, Wei‐Ting Hwang, Dan T. Vogl, Adam Waxman, Simon F. Lacey, Vanessa Gonzalez, Joseph A. Fraietta, Minnal Gupta, Irina Kulikovskaya, Lifeng Tian, Fang Chen, Natalka Koterba, Robert L. Bartoszek, Margaret Patchin, Rong Xu, Gabriela Plesa, Don L. Siegel, Andrea Brennan, Anne Marie Nelson, Regina Ferthio, Angela Cosey, Kim-Marie Shea, Rachel Leskowitz, Megan Four, Wesley V. Wilson, Fei Miao, Eric Lancaster, Beatriz M. Carreno, Gerald P. Linette, Elizabeth O. Hexner, Regina M. Young, Dexiu Bu, Keith G. Mansfield, Jennifer L. Brogdon, Carl H. June, Michael C. Milone, Edward A. Stadtmauer - Blood Cancer Discovery 2022 cited by 76

  15. Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma

    Authors: Paul G. Richardson, Pieter Sonneveld, Michael W. Schuster, David Irwin, Edward A. Stadtmauer, Thierry Façon, Jean‐Luc Harousseau, Dina Ben‐Yehuda, Sagar Lonial, Hartmut Goldschmidt, Donna Reece, Jesús F. San Miguel, Joan Bladé, Mario Boccadoro, Jamie Cavenagh, William S. Dalton, Anthony Boral, Dixie Esseltine, Jane Porter, David P. Schenkein, Kenneth C. Anderson - New England Journal of Medicine 2005 cited by 2,493

  16. Cytokine-mediated CAR T therapy resistance in AML

    Authors: Anand Bhagwat, Leonel Torres, Olga Shestova, Maksim Shestov, Patrick Mellors, Han R Fisher, Saamia Farooki, Benjamin F. Frost, Michael R. Loken, Avery L. Gaymon, Diane Frazee, Walter Rogal, Noelle V. Frey, Elizabeth O. Hexner, Selina M. Luger, Alison W. Loren, Mary Ellen Martin, Shannon R. McCurdy, Alexander E. Perl, Edward A. Stadtmauer, Jennifer L. Brogdon, Joseph A. Fraietta, Wei‐Ting Hwang, Don L. Siegel, Gabriela Plesa, Richard Aplenc, David L. Porter, Carl H. June, Saar Gill - Nature Medicine 2024 cited by 81

  17. Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): a multicentre, multicohort, open-label, phase 1/2 trial

    Authors: Sagar Lonial, Rakesh Popat, Cyrille Hulin, Sundar Jagannath, Albert Oriol, Paul G. Richardson, Thierry Façon, Katja Weisel, Jeremy T. Larsen, Monique C. Minnema, Al‐Ola Abdallah, Ashraf Badros, Stefan Knop, Edward A. Stadtmauer, Yiming Cheng, Michael Amatangelo, Min Chen, Tuong Vi Nguyen, Alpesh Amin, Teresa Peluso, Niels W.C.J. van de Donk - The Lancet Haematology 2022 cited by 92

  18. Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma

    Authors: Alfred L. Garfall, Marcela V. Maus, Wei‐Ting Hwang, Simon F. Lacey, Yolanda D. Mahnke, J. Joseph Melenhorst, Zhaohui Zheng, Dan T. Vogl, Adam D. Cohen, Brendan M. Weiss, Karen Dengel, Naseem Kerr, Adam Bagg, Bruce L. Levine, Carl H. June, Edward A. Stadtmauer - New England Journal of Medicine 2015 cited by 638

  19. Carfilzomib-Associated Cardiovascular Adverse Events

    Authors: Adam Waxman, Suparna C. Clasen, Wei‐Ting Hwang, Alfred L. Garfall, Dan T. Vogl, Joseph R. Carver, Rupal O’Quinn, Adam D. Cohen, Edward A. Stadtmauer, Bonnie Ky, Brendan M. Weiss - JAMA Oncology 2017 cited by 276

  20. Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia

    Authors: Andrew Matthews, Alexander E. Perl, Selina M. Luger, Alison W. Loren, Saar Gill, David L. Porter, Daria V. Babushok, Ivan Maillard, Martin Carroll, Noelle V. Frey, Elizabeth O. Hexner, Mary Ellen Martin, Shannon R. McCurdy, Edward A. Stadtmauer, Vikram R. Paralkar, Ximena Jordan Bruno, Wei‐Ting Hwang, David M. Margolis, Keith W. Pratz - Blood Advances 2022 cited by 100

  21. Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma

    Authors: Philip L. McCarthy, Kouros Owzar, Craig C. Hofmeister, David D. Hurd, Hani Hassoun, Paul G. Richardson, Sergio Giralt, Edward A. Stadtmauer, Daniel J. Weisdorf, Ravi Vij, Jan S. Moreb, Natalie S. Callander, Koen van Besien, Teresa Gentile, Luis Isola, Richard T. Maziarz, Don A. Gabriel, Asad Bashey, Heather Landau, Thomas Martin, Muzaffar H. Qazilbash, Denise Levitan, Brian McClune, Robert Schlossman, Vera Hárs, John Postiglione, Chen Jiang, Elizabeth Bennett, Susan Barry, Linda R. Bressler, Michael E. Kelly, Michele Seiler, Cara A. Rosenbaum, Parameswaran Hari, Marcelo C. Pasquini, Mary M. Horowitz, Thomas C. Shea, Steven M. Devine, Kenneth C. Anderson, Charles Linker - New England Journal of Medicine 2012 cited by 1,143

  22. Long-term safety and activity of NY-ESO-1 SPEAR T cells after autologous stem cell transplant for myeloma

    Authors: Edward A. Stadtmauer, Thomas Faitg, Daniel E. Lowther, Ashraf Badros, Karen Chagin, Karen Dengel, Malini Iyengar, Luca Melchiori, Jean‐Marc Navenot, Elliot Norry, Trupti Trivedi, Ruoxi Wang, Gwendolyn K. Binder, Rafael G. Amado, Aaron P. Rapoport - Blood Advances 2019 cited by 88

  23. Long-term safety of lentiviral or gammaretroviral gene-modified T cell therapies

    Authors: Julie K. Jadlowsky, Elizabeth O. Hexner, Amy Marshall, Stephan A. Grupp, Noelle V. Frey, James L. Riley, Elizabeth Veloso, Holly McConville, Walter Rogal, Cory Czuczman, Wei‐Ting Hwang, Yimei Li, Rachel Leskowitz, Olivia Farrelly, Jayashree Karar, Shannon Christensen, Julie S. Barber-Rotenberg, Avery L. Gaymon, Naomi Aronson, Wendy Bernstein, J. Joseph Melenhorst, Aoife M. Roche, J.K. Everett, Sonja A. Zolnoski, Alexander McFarland, Shantan Reddy, Angelina Petrichenko, Emma J. Cook, Carole Lee, Vanessa Gonzalez, Kathleen A. Alexander, Irina Kulikovskaya, Ángel Ramírez-Fernández, Janna Minehart, Marco Ruella, Saar Gill, Stephen J. Schuster, Adam D. Cohen, Alfred L. Garfall, Payal D. Shah, David L. Porter, Shannon L. Maude, Bruce L. Levine, Don L. Siegel, Anne Chew, S.J. McKenna, Lester Lledo, Megan M. Davis, Gabriela Plesa, Friederike Herbst, Edward A. Stadtmauer, Pablo Tebas, Amanda M. DiNofia, A. Haas, Naomi B. Haas, Regina M. Myers, Donald M. O’Rourke, Jakub Svoboda, János L. Tanyi, Richard Aplenc, Jeffrey M. Jacobson, Andrew H. Ko, Roger B. Cohen, Carl H. June, Frederic D. Bushman, Joseph A. Fraietta - Nature Medicine 2025 cited by 71

  24. Efficacy and Safety of Gemtuzumab Ozogamicin in Patients With CD33-Positive Acute Myeloid Leukemia in First Relapse

    Authors: Eric L. Sievers, Richard A. Larson, Edward A. Stadtmauer, Elihu H. Estey, Bob Löwenberg, Hervé Dombret, Chatchada Karanes, Matthias Theobald, John M. Bennett, Matthew L. Sherman, Mark S. Berger, Catharine B. Eten, Michael R. Loken, Jacques J. M. van Dongen, Irwin D. Bernstein, Frederick R. Appelbaum, for the Mylotarg Study Group - Journal of Clinical Oncology 2001 cited by 893